DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN Germany ONLY.
Information about the NuvaxovidTM ▼ COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)
NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, and as a booster dose approximately 6 months after the second dose in individuals 18 years of age and older.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Germany.
Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel
Tel: +49 6103 77 0
Fax: +49 6103 77 1234
Tel: +49 800 1813940
09:00 - 17:00
Monday - Friday